爱博医疗：2024H1业绩符合预期，看好公司多轮驱动高增长

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook on its performance and growth potential [5]. Core Insights - The company's H1 2024 performance met expectations, with a revenue of 686 million yuan, a year-on-year increase of 69%, and a net profit attributable to shareholders of 208 million yuan, up 28% year-on-year [5]. - The growth in revenue is driven by significant increases in the sales of cataract lenses and contact lenses, with the latter seeing a remarkable year-on-year growth of 956.9% [5]. - The company's gross margin decreased to 69.68% from 83.15% in the previous year, influenced by price reductions from centralized procurement and a higher proportion of revenue from contact lenses [5]. - Research and development efforts are ongoing, with a total investment of 68.6 million yuan in H1 2024, reflecting a year-on-year increase of 25.43% [5]. Financial Summary - For H1 2024, the company reported total revenue of 686 million yuan, with a year-on-year growth rate of 68.5% [6]. - The projected net profit for 2024 is estimated at 395 million yuan, with a year-on-year growth rate of 29.9% [5][6]. - The company's earnings per share (EPS) for 2024 is projected to be 2.08 yuan, with a gross margin forecasted to be around 69.1% [5][6].